Vertex Pharmaceuticals Inc 10-Q for FY2026 Q3
Vertex Pharmaceuticals Inc (VRTX)
10-Q
2026-11-03
For: 2026-09-30
View Original
Added on
November 03, 2026
About this 10-Q
Vertex Pharmaceuticals Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Vertex Pharmaceuticals Inc reported Q3 2026 total revenues of $3.4 billion versus $3.1 billion in Q3 2025. The Crinetics Acquisition added compensation and transaction expenses, while cash, cash equivalents and marketable securities fell to $9.8 billion on September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $3.44B
- up 11.8% from $3.08B a year earlier
- Net income
- $653.6M
- down 39.6% from net income of $1.08B a year earlier
- Diluted EPS
- $2.56
- down 39.0% from $4.20 a year earlier